Decheng Capital Overview
- Investor Type
-
Venture Capital
- Status
-
Active
- Professionals
-
13
- Investments
-
146
- Portfolio
-
47
- Exits
-
54
Decheng Capital General Information
Company Description
Founded in 2012, Decheng Capital is a venture capital firm based in Menlo Park, California. The firm seeks to invest in early-stage life science companies and growth-stage healthcare companies. This firm is a Registered Investment Adviser (RIA).
Business Details
Website
www.decheng.comYear Founded
Investor Status
Primary Investor Type
Other Investor Types
Corporate Office
- 3000 Sand Hill Road
- Building 2, Suite 110
- Menlo Park, CA 94025
- United States
Decheng Capital Investments (146)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| Phrontline Biopharma | 13-Nov-2026 | Early Stage VC | Drug Discovery | Generating Revenue | ||
| Synphatec | 28-Sep-2026 | Drug Discovery | Generating Revenue | |||
| NUTSHELL Therapeutics | 15-Sep-2026 | Drug Discovery | Generating Revenue | |||
| Remix Therapeutics | 24-Jun-2026 | Drug Discovery | Clinical Trials - General | |||
| Serapha Bio | 22-Jun-2026 | Discovery Tools (Healthcare) | Generating Revenue | |||
| Sicheng Aerospace | 15-May-2026 | Aerospace and Defense | Startup | |||
| Cellares | 15-Apr-2026 | Biotechnology | Generating Revenue | |||
| VIVACTA Biotechnology | 13-Apr-2026 | Drug Discovery | Generating Revenue | |||
| Syneron | 31-Mar-2026 | Early Stage VC | Drug Discovery | Generating Revenue | ||
| Phrontline Biopharma | 21-Nov-2025 | Early Stage VC | Drug Discovery | Generating Revenue |
Decheng Capital Exits (54)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| FireFly Bio | 29-Jul-2026 | Merger/Acquisition | |
| IMPACT Therapeutics | 13-May-2026 | ||
| Nalu Medical | 27-Jan-2026 | ||
| AccuraGen | 01-Dec-2025 | ||
| ConjugateBio | 14-Jul-2025 | ||
| Aardvark Therapeutics | 13-Feb-2025 | ||
| ImmPACT Bio | 31-Oct-2024 | ||
| Upstream Bio | 11-Oct-2024 | ||
| AnHeart Therapeutics | 09-Apr-2024 | Merger/Acquisition | |
| Xtremity | 28-Mar-2024 | Buyout/LBO |
Decheng Capital Fund Performance
| Fund Name | Vintage | Size | Dry Powder | DPI | RVPI | TVPI | IRR |
|---|
Decheng Capital Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
Decheng Capital Co-Investors (167)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| OrbiMed | 6 |
|
|
||
| Samsara BioCapital |
|
|
|||
| Surveyor Capital |
|
|
|||
| Foresite Capital |
|
|
|||
| General Atlantic |
|
|
Decheng Capital FAQs
-
What is Decheng Capital?
Founded in 2012, Decheng Capital is a venture capital firm based in Menlo Park, California.
-
When was Decheng Capital founded?
Decheng Capital was founded in 2012.
-
Where is Decheng Capital headquartered?
Decheng Capital is headquartered in Menlo Park, CA.
-
What is Decheng Capital's total asset value?
Decheng Capital has around in total assets under management.
-
How many investments has Decheng Capital made?
Decheng Capital has made 146 investments.
-
What has Decheng Capital invested in?
Decheng Capital has made numerous investments in companies like Phrontline Biopharma, Synphatec, and NUTSHELL Therapeutics within the Drug Discovery industry.
-
What has Decheng Capital invested in recently?
Decheng Capital's latest investment was on 13-Nov-2026 in Phrontline Biopharma, a company within the Drug Discovery industry.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
